These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 7202941)

  • 1. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease.
    Trnka YM; LaMont JT
    Gastroenterology; 1981 Apr; 80(4):693-6. PubMed ID: 7202941
    [No Abstract]   [Full Text] [Related]  

  • 2. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease.
    Meyers S; Mayer L; Bottone E; Desmond E; Janowitz HD
    Gastroenterology; 1981 Apr; 80(4):697-70. PubMed ID: 7202942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Clostridium difficile and Campylobacter jejuni in relapses of inflammatory bowel disease.
    Gurian L; Klein K; Ward TT
    West J Med; 1983 Mar; 138(3):359-60. PubMed ID: 6858121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clostridium difficile and inflammatory bowel disease.
    Bartlett JG
    Gastroenterology; 1981 Apr; 80(4):863-5. PubMed ID: 7202955
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease.
    LaMont JT; Trnka YM
    Lancet; 1980 Feb; 1(8165):381-3. PubMed ID: 6101841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacitracin treatment of antibiotic-associated colitis and diarrhea caused by Clostridium difficile toxin.
    Chang TW; Gorbach SL; Bartlett JG; Saginur R
    Gastroenterology; 1980 Jun; 78(6):1584-6. PubMed ID: 7372074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clostridium difficile infection frequency in patients with nosocomial infections or using antibiotics.
    Gursoy S; Guven K; Arikan T; Yurci A; Torun E; Baskol M; Ozbakir O; Yucesoy M
    Hepatogastroenterology; 2007 Sep; 54(78):1720-4. PubMed ID: 18019703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clostridium difficile infections: emerging epidemiology and new treatments.
    Cohen MB
    J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S63-5. PubMed ID: 19300129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Percutaneous endoscopic colostomy for treatment of an antibiotic-induced pseudomembranous colitis].
    Prassler R
    Dtsch Med Wochenschr; 2008 Oct; 133(44):2268-71. PubMed ID: 18946851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent pseudomembranous colitis unassociated with prior antibiotic therapy.
    Moskovitz M; Bartlett JG
    Arch Intern Med; 1981 Apr; 141(5):663-4. PubMed ID: 7224749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of Clostridium difficile infection in the relapse of ulcerative colitis].
    Vilalta Castel E; Alcázar Montero MS; Navarro Gaspar C; Gimeno Aranguez M
    An Med Interna; 2002 Dec; 19(12):637-9. PubMed ID: 12593034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clostridium difficile infections. Current aspects].
    Fulgione V
    Recenti Prog Med; 1998; 89(7-8):385-94. PubMed ID: 9691734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases.
    Ricciardi R; Ogilvie JW; Roberts PL; Marcello PW; Concannon TW; Baxter NN
    Dis Colon Rectum; 2009 Jan; 52(1):40-5. PubMed ID: 19273954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Clostridium difficile toxin by an indigenously developed latex agglutination assay.
    Vaishnavi C; Kochhar R; Bhasin DK; Thapa BR; Singh K
    Trop Gastroenterol; 1999; 20(1):33-5. PubMed ID: 10464446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical spectrum of Clostridium difficile colitis in immunocompromised patients.
    Schweitzer MA; Sweiss I; Silver DL; Stellato TA
    Am Surg; 1996 Jul; 62(7):603-7; discussion 607-8. PubMed ID: 8651560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces].
    Nieuwdorp M; van Nood E; Speelman P; van Heukelem HA; Jansen JM; Visser CE; Kuijper EJ; Bartelsman JF; Keller JJ
    Ned Tijdschr Geneeskd; 2008 Aug; 152(35):1927-32. PubMed ID: 18808083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relapsing infections with Clostridium difficile].
    Visser WE; Dingemans-Dumas AM; Bac DJ
    Ned Tijdschr Geneeskd; 2005 Oct; 149(43):2381-5. PubMed ID: 16277125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Past, present, and future therapies for Clostridium difficile-associated disease.
    Surowiec D; Kuyumjian AG; Wynd MA; Cicogna CE
    Ann Pharmacother; 2006 Dec; 40(12):2155-63. PubMed ID: 17148650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.
    Al-Nassir WN; Sethi AK; Nerandzic MM; Bobulsky GS; Jump RL; Donskey CJ
    Clin Infect Dis; 2008 Jul; 47(1):56-62. PubMed ID: 18491964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.
    McFarland LV; Elmer GW; Surawicz CM
    Am J Gastroenterol; 2002 Jul; 97(7):1769-75. PubMed ID: 12135033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.